Oxygen therapy via high flow nasal cannula (HFNC) is used for hypoxemic respiratory failure, acute exacerbations of chronic obstructive pulmonary disease, prophylactically against hypoxemia following extubation, sleep apnea, and respiratory failure secondary to acute heart failure. This method has been found to increase patient comfort and tolerance, reduce respiratory work, and decrease the need for respiratory support in respiratory failure episodes secondary to etiologies.
Administration of oxygen therapy via HFNC is achieved by using an air-oxygen mixer, an active humidifier, a heated circuitry, and a special nasal cannula. HFNC therapy has been shown to increase lung compliance and to improve gas exchange. It was also found to reduce nasopharyngeal dead space and to increase intrathoracic pressure, thereby forming a low-level positive end-expiratory pressure. Because of poor mask tolerance, however, noninvasive ventilation (NIV) is sometimes inapplicable. Another major difference between NIV and HFNC is the interface. While interfaces for NIV increase anatomical dead space, those for HFNC actually decrease dead space. Since neither inspiratory push nor expiratory pull is effective in such an open circuit, HFNC cannot actively enhance inspiratory tidal volume 1,2 .
Since especially young infants' respiratory muscles are poor in oxidative fibers, they may develop respiratory distress more easily. HFNC preserves mucociliary function, prevents atelectasis, reduces respiratory work, and favorably affects energy consumption 3 .
This study aimed to determine the efficacy and safety of oxygen therapy via high flow nasal cannula in pediatric patients having acute respiratory failure.
Material and Methods
This study included patients aged between 1 month and 17 years who were admitted to our pediatric intensive care unit upon a diagnosis of acute hypoxic respiratory failure (PaO2<55 mmHg in room air) between January 2015 and January 2016. Patients with upper airway obstruction, apnea, hemodynamic instability, hypercapnic respiratory failure, contraindications for NIV, and altered consciousness were excluded from the trial. HFNC therapy was applied via a nasal cannula (Optiflow, Fisher & Paykel Healthcare, Germany). The size of the nasal cannula was set to half of that of nostrils; humidity of inspired mixture was set at 34-37 °C; and FiO 2 was titrated to attain a SatO 2 of 92-97%. Initial flow rate was set at 2 L/kg/min for infants and 1 L/kg/min for children; it was then adjusted according to arterial blood gas checks and a change in clinical status. Arterial blood gas parameters, respiratory rates (RR), heart rates (HR), systolic, diastolic, and mean arterial pressures (SBP, DBP, MAP), dyspnea scores, fractional oxygen indices (FiO 2 ), and oxygen saturations (SatO 2 ) were recorded at 0 minute, 30 minutes, and 12 hours. A switch to invasive ventilation was made when clinical or laboratory parameters deteriorated. Treatment failure criteria were determined by withdrawal due to major complications, poor tolerance, and inability to stabilize the progression of respiratory failure requiring tracheal intubation. 
Results
The study included a total of 50 patients of whom 24 (48%) were female and 26 (52%) were male. (Table IV) .
No significant difference was found in terms of healing in 30 th minute and 12 th hour FiO 2 levels between the cases of which treatments were successful and unsuccessful (p>0.05). When no significant difference was found in terms of the decrease that was found in 30 th minute scores with regard to 0 th minute between the cases of which treatments were successful and unsuccessful, the decrease level in 12 th minute score in the group of which treatment was successful, was statistically more significant (p:0.004). (Table V) .
Discussion
So far, multiple studies have investigated the efficacy of non-invasive ventilation in various types of acute respiratory failure (ARF) [4] [5] [6] . However, the experience with children is limited in this subject. NIV has been shown to favorably affect prognosis following extubation, in acute exacerbation of chronic respiratory failure, and hypoxic respiratory failure 7, 8 .
It was reported that in pediatric patients younger than 6 months, pharyngeal pressure was increased as flow increased, and at a level of 7 L/min the mean pressure and PEEP pressure were elevated to 4 and 6.5 cmH 2 O, respectively 9 . Furthermore, when humidified and heated oxygen-air mixture was Fraction of inspired oxygen administered to trachea, upper airway resistance was also reduced 10 . In a study published in 2011 where HFNC therapy was administered to infants, only 6 (3.6%) of 166 patients with bronchiolitis required invasive ventilation 11 .
Various studies have demonstrated that HFNC reduced the need for intubation by 8-19% in patients with acute respiratory failure 12, 13 . In children younger than 2 years of age HFNC failure occurs within the first 7-14 hours of therapy onset whereas NIV techniques usually fail within the first 2 hours 14 . The HFNC therapy failed a need for intubation emerged in 20% of patients in our study. We suggest that this resulted from the severity of our patients' clinical condition necessitating intensive care unit follow-up. In our unit, it has been detected that intubation rate was 73% in period when HFNC was not used and that it became 70% after HFNC was used.
In a prospective trial dated 2010 where the efficacy of NIV was evaluated in 47 pediatric patients with ARF, treatment failure was correlated to younger age and the need of >0.60 cm H 2 O FiO 2 ; intubation was required in 9 (19.1%) of 47 patients in that study 15 .
We did not detect any correlation between treatment failure and age or FiO 2 requirement.
Lenglet et al. 16 reported that when HFNC respiratory rate fell from 28 breath/min to 25 breath/min, SpO 2 rose from 90% to 97% (p<0.001), and this method was well tolerated without any side effects. Similarly, Mayfield et al. 17 reported that heart rate fell from 158 bpm to 144 bpm in the HFNC responders whereas it rose from 159 bpm to 162 bpm in HFNC non-responders (p=0.02). Our study similarly demonstrated a drop in heart rate with HFNC, so that HR fell from 137 bpm at baseline to 128 bpm at 30 minutes and 118 bpm at 12 hours. Likewise, RR was reduced to 38/min at 30 minutes and 35/min at 12 hours from 41/min at baseline. Mean dyspnea score was also reduced from 8 at baseline to 7 at 30 minutes and 4 at 12 hours.
Frat et al. 18 investigated the clinical outcomes of high flow nasal oxygen therapy, noninvasive ventilation, and standard oxygen therapy via mask in 310 intensive care unit patients with non-hypercapnic acute respiratory failure. They showed that high flow nasal oxygen therapy led to a non-significant reduction in the frequency of endotracheal intubation compared to other treatment methods. In a postHoc analysis of 238 patients having severe hypoxemia (PaO 2 / FiO 2 ≤200 mmHg) at baseline, intubation rate was significantly lower in the high flow nasal oxygen group than the other groups (p=0.009). Furthermore, high flow nasal oxygen therapy increased the number of ventilator-free days, reduced 90-day mortality compared to the other two groups, and enhanced patient comfort.
Abboud et al. 19 , in a study comprising 113 patients who received HFNC therapy, reported that patients that necessitated intubation during follow-up had a greater number of breath per minute, a higher PaCO 2 level, and had more criteria for pediatric mortality risk. In another study it was reported that patients whose tachycardia did not regress at 60 and 90 minutes needed intubation 20 . We did not find any correlation between treatment failure and initial blood gas parameters, Silverman and Wood-Downes score, FiO 2 need, HR, and RR. We think that this situation stems from inadequacy of the parameters used, which is one of the weak points of the study.
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